US FDA Approves First Oral PCSK9 Inhibitor for Cholesterol

The U.S. Food and Drug Administration approved Merck's cholesterol-lowering drug Lipfendra, known as enlicitide, on July 16, 2026 ^[4].

This approval marks a significant shift in cardiovascular care by providing a potent oral alternative to injectable therapies and traditional statins. For high-risk patients who cannot reach target cholesterol levels through standard means, the drug offers a more convenient delivery method without sacrificing efficacy.

Lipfendra is the first oral PCSK9 inhibitor to receive regulatory approval ^[3]. Unlike statins, which block the production of cholesterol in the liver, this medication utilizes a different mechanism to lower low-density lipoprotein (LDL) cholesterol ^[2]. The drug is administered as a once-daily pill ^[6].

The FDA approved the treatment for adult patients with hypercholesterolemia ^[5]. It is specifically intended for high-risk individuals who require more aggressive LDL lowering than what is typically achieved with statins ^[5].

Medical professionals have long sought an oral version of PCSK9 inhibitors. While previous inhibitors in this class were effective, they required periodic injections, which often limited patient adherence. The transition to a pill format is expected to increase the accessibility of this specific chemical pathway for those at risk of heart disease.

Merck developed the drug to address the gap in treatment for patients who are statin-intolerant, or whose cholesterol remains dangerously high despite maximum statin therapy ^[5]. The approval allows the company to bring the medication to the U.S. market immediately.